X |
Filing Date |
Trade Date |
Ticker |
Insider Name | Title |
Trade Type |
Price |
Qty |
Owned |
ΔOwn |
Value |
1d |
1w |
1m |
6m |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
2025-04-02 | VTYX | Nuss John | Chief Scientific Officer | S - Sale | $1.07 | -1,887 | 467,226 | 0% | -$2,019 | ||||||
2024-12-27 | VTYX | Nuss John | Chief Scientific Officer | S - Sale | $2.36 | -21,119 | 464,582 | -4% | -$49,841 | ||||||
2024-12-23 | VTYX | Gujrathi Sheila | Dir | P - Purchase | $2.31 | +130,000 | 130,000 | New | +$300,573 | ||||||
| D | 2024-12-19 | VTYX | Nuss John | Chief Scientific Officer | S - Sale+OE | $2.26 | -13,161 | 485,701 | -3% | -$29,682 | |||||
| M | 2024-11-22 | VTYX | Mohan Raju | CEO, Pres | P - Purchase | $1.92 | +500,000 | 2,175,028 | +30% | +$959,889 | |||||
2024-04-02 | VTYX | Krueger Christopher W | Chief Business Officer | S - Sale | $5.40 | -1,651 | 284,999 | -1% | -$8,921 | ||||||
2024-04-02 | VTYX | Nuss John | Chief Scientific Officer | S - Sale | $5.40 | -1,651 | 264,998 | -1% | -$8,921 | ||||||
2024-04-02 | VTYX | Mohan Raju | CEO, Pres | S - Sale | $5.40 | -4,312 | 1,578,250 | 0% | -$23,299 | ||||||
2024-04-02 | VTYX | Auster Martin | CFO | S - Sale | $5.40 | -1,405 | 24,303 | -5% | -$7,592 | ||||||
2023-12-20 | VTYX | Nuss John | Chief Scientific Officer | S - Sale | $2.12 | -17,628 | 262,118 | -6% | -$37,334 | ||||||
2023-12-20 | VTYX | Krueger Christopher W | Chief Business Officer | S - Sale | $2.12 | -5,293 | 282,119 | -2% | -$11,210 | ||||||
2023-12-20 | VTYX | Mohan Raju | CEO, Pres | S - Sale | $2.12 | -58,860 | 1,570,719 | -4% | -$124,660 | ||||||
2023-10-09 | VTYX | Nsv Partners III LP | 10% | S - Sale | $30.03 | -49,152 | 8,439,635 | -1% | -$1,475,858 | ||||||
2023-10-09 | VTYX | Subramaniam Somu | Dir, 10% | S - Sale | $30.03 | -49,152 | 8,439,635 | -1% | -$1,475,858 | ||||||
| D | 2023-10-05 | VTYX | Mohan Raju | CEO | S - Sale+OE | $29.11 | -30,000 | 1,512,911 | -2% | -$873,231 | |||||
| D | 2023-10-03 | VTYX | Krueger Christopher W | Chief Business Officer | S - Sale+OE | $29.98 | -15,000 | 276,548 | -5% | -$449,699 | |||||
| D | 2023-10-03 | VTYX | Nuss John | Chief Scientific Officer | S - Sale+OE | $29.99 | -10,000 | 244,815 | -4% | -$299,933 | |||||
2023-09-18 | VTYX | Subramaniam Somu | Dir, 10% | S - Sale | $37.81 | -56,665 | 8,488,787 | -1% | -$2,142,634 | ||||||
2023-09-18 | VTYX | Nsv Partners III LP | 10% | S - Sale | $37.81 | -56,665 | 8,488,787 | -1% | -$2,142,634 |
| A | Amended filing |
| D | Derivative transaction in filing (usually option exercise) |
| E | Error detected in filing |
| M | Multiple transactions in filing; earliest reported transaction date and weighted average transaction price |
| S - Sale | Sale of securities on an exchange or to another person |
| S - Sale+OE | Sale of securities on an exchange or to another person (after option exercise) |
| F - Tax | Payment of exercise price or tax liability using portion of securities received from the company |
| P - Purchase | Purchase of securities on an exchange or from another person |